Precision BioSciences, Inc.

158 articles with Precision BioSciences, Inc.

• Precision BioSciences to Host Virtual Webcast and Conference Call to Review Interim Phase 1/2a PBCAR0191 CAR T Data and Provide CAR T Program Updates on Saturday, December 11, 2021

  12/6/2021

  Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company using its ARCUS® genome editing platform to develop allogeneic CAR T and in vivo gene editing therapies, today announced it will review interim data results presented at the 63rd American Society of Hematology Annual Meeting.

• Precision BioSciences to Present Preclinical Gene Editing Data on its ARCUS-Based Chronic Hepatitis B Program at the HEP DART 2021 Conference

  12/3/2021

  Precision BioSciences, Inc. today announced it will present preclinical data for its chronic hepatitis B virus (HBV) program at the HEP DART 2021 conference taking place in Cabo San Lucas, Mexico, December 5 – 9, 2021.

• Precision BioSciences Reports Third Quarter 2021 Financial Results and Provides Business Update

  11/10/2021

  Precision BioSciences, Inc. today announced financial results for the third quarter ended September 30, 2021 and provided a business update.

• Precision BioSciences to Highlight Capabilities of ARCUS Gene Editing for Allogeneic CAR T Cell Immunotherapies at The Society for Immunotherapy of Cancer 36th Annual Meeting

  11/9/2021

  Precision BioSciences to Highlight Capabilities of ARCUS Gene Editing for Allogeneic CAR T Cell Immunotherapies at The Society for Immunotherapy of Cancer 36th Annual Meeting

• Precision BioSciences Appoints Sam Wadsworth, Ph.D. and Shari Lisa Piré, J.D. to Board of Directors

  11/8/2021

  Precision BioSciences, Inc. today announced that Sam Wadsworth, Ph.D., Chief Scientific Officer of Ultragenyx Gene Therapy Shari Lisa Piré, J.D., Chief Legal & Sustainability Officer at Plume Design, have been appointed to the Company’s Board of Directors.

• Precision BioSciences Announces Two Oral Presentations Highlighting Updated Interim Data from Lead PBCAR0191 CAR T Immunotherapy

  11/4/2021

  Precision BioSciences Announces Two Oral Presentations Highlighting Updated Interim Data from Lead PBCAR0191 CAR T Immunotherapy for Relapsed and Refractory B-cell Malignancies at the 63 rd Annual Meeting of the American Society of Hematology

• Precision BioSciences to Report Third Quarter 2021 Financial Results on November 10, 2021 and Participate in the Stifel 2021 Virtual Healthcare Conference on November 16, 2021

  11/3/2021

  Precision BioSciences, Inc. today announced that it will publish financial results for the third quarter 2021 and provide a business update on November 10, 2021.

• Precision BioSciences to Present at the Jefferies Virtual Gene Therapy/Editing Summit on Thursday, October 27, 2021

  10/21/2021

  Precision BioSciences, Inc. today announced that Derek Jantz, Ph.D., Chief Scientific Officer and Co-Founder, will present at the Jefferies Virtual Gene Therapy/Gene Editing Summit, being held October 27-28, 2021.

• Precision BioSciences Announces Grant of Inducement Award for Newly Appointed Chief Executive Officer Pursuant to Nasdaq Listing Rule 5635(c)(4)

  9/27/2021

  Precision BioSciences, Inc. today announced an inducement grant for Michael Amoroso, newly appointed President and Chief Executive Officer of Precision BioSciences.

• Precision BioSciences Appoints Michael Amoroso Chief Executive Officer

  9/27/2021

  Precision BioSciences, Inc. today announced that Michael Amoroso has been named as the Company’s President and Chief Executive Officer and a member of the Precision BioSciences Board of Directors, in each case effective October 15, 2021.

• Precision BioSciences to Present at H.C. Wainwright 23rd Annual Global Investment Conference

  9/10/2021

  Precision BioSciences to Present at H.C. Wainwright 23rd Annual Global Investment Conference

• Precision BioSciences Outlines Clinical Development Strategy for In Vivo Gene Editing Pipeline

  9/9/2021

  Precision BioSciences today provided strategic business updates on its in vivo gene editing pipeline during the Company’s first gene editing R&D event.

• Precision BioSciences and iECURE Announce License and Collaboration Agreement to Develop ARCUS-Based Gene Editing Therapies

  9/9/2021

  iECURE to License Precision’s PCSK9-Directed ARCUS Nuclease and Pursue Four Gene Insertion Programs Focused on Liver Diseases; Precision Retains Rights Across All Indications Except Those Licensed to iECURE

• 

  Precision Signs Another Collab for ARCUS Genome Editing Platform

  9/9/2021

  Durham, N.C.-based Precision BioSciences announced a license and collaboration deal with Philadelphia-based iECURE and described its clinical development plans.

• Precision BioSciences and Tiziana Life Sciences Announce Exclusive License Agreement to Evaluate Foralumab, a Novel, Fully Human Anti-CD3 Monoclonal Antibody, in Conjunction with Allogeneic CAR T Candidates for Cancer Treatment

  9/2/2021

  Precision BioSciences, Inc. and Tiziana Life Sciences plc announced an exclusive license agreement to explore Tiziana’s foralumab, a fully human anti-CD3 monoclonal antibody, as an agent to induce tolerance of allogeneic CAR T cells to potentially improve the clinical outcome of CAR T cell therapy.

• Precision BioSciences to Host In Vivo Gene Editing R&D Event on September 9, 2021

  8/25/2021

  Precision BioSciences to Host In Vivo Gene Editing R&D Event on September 9, 2021

• Precision BioSciences Reports Second Quarter 2021 Financial Results and Provides Business Update

  8/12/2021

  Precision BioSciences, Inc. today announced financial results for the second quarter ended June 30, 2021 and provided a business update.

• Precision BioSciences to Report Second Quarter 2021 Financial Results on August 12, 2021

  8/5/2021

  Precision BioSciences, Inc., a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies with its ARCUS® genome editing platform, announced that it will publish financial results for the second quarter 2021 and provide a business update on August 12, 2021.

• Precision BioSciences Doses First Patient in Phase 1 Allogeneic CAR T Clinical Trial of PBCAR19B Immune Evading Stealth Cell for Relapsed/Refractory Non-Hodgkin Lymphoma

  7/1/2021

  Precision BioSciences, Inc., a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies with its ARCUS® genome editing platform, announced that the first patient has been dosed in its Phase 1 clinical trial with PBCAR19B, an immune evading allogeneic CAR T stealth cell candidate for patients with relapsed/refractory non-Hodgkin lymphoma.

• Precision BioSciences and SpringWorks Therapeutics Dose First Patient in Expanded Phase 1/2a Clinical Trial Evaluating PBCAR269A with Nirogacestat in Patients with Relapsed/Refractory Multiple Myeloma

  6/28/2021

  Precision BioSciences, Inc. and SpringWorks Therapeutics, Inc. announced that the first patient has been dosed in the combination arm of Precision’s Phase 1/2a trial evaluating PBCAR269A.